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Objectives: This study aimed to evaluate the specificity, sensitivity, cost, and
turn-around time of three methods of gene polymorphism analysis and to study
the relationship between IL28B rs12979860 and SVR rate to pegIFN-a/RVB ther-
apy among patients with chronic hepatitis C.
Methods: A total of 100 samples from chronic hepatitis C patients were analyzed
in parallel using the three methods: direct sequencing, real-time polymerase
chain reaction (PCR), amplification refractory mutation system (ARMS)-PCR.
Results: The different profiles for IL28B rs12979860 alleles (CC, CT, and TT)
obtained with PCR-RFLP, ARMS-PCR, and direct sequencing were consistent
among the three methods. Prevalence of rs12979860 genotypes CC, CT and TT in
HCV genotype 1a was 10(19.6%), 35(68.6%), and six (11.8%), respectively, and in
HCV genotype 31, it was 13(26.5%), 31(63.3%), and five (10.2%), respectively. No
significant difference was seen between rs12979860 genotype and HCV genotype
(p Z 0.710).
Conclusion: Screening by ARMS e PCR SNOP detection represents the most
efficient and reliable method to determine HCV polymorphisms in routine clinical
practice.ari).
ase Control and Prevention. Published by Elsevier Korea LLC. This is an open access article
reativecommons.org/licenses/by-nc-nd/4.0/).
84 A. Fateh, et al1. Introduction from December 2011 to June 2013. The exclusionHepatitis C virus (HCV) infection is one of the major
causes of chronic liver disease. The long-term impact of
HCV infection is variable, ranging from minimal his-
tological changes to extensive fibrosis and cirrhosis with
or without hepatocellular carcinoma (HCC). The num-
ber of chronically infected persons worldwide is esti-
mated to be 160 million (2.35% of the world
population), but most are unaware of their infection [1].
The current treatment standard of pegylated inter-
feron (pegIFN)-a and ribavirin (RBV) produces only a
50% response rate in genotype 1 and 80% response rate
in genotype 3 individuals [2]. In addition, combination
therapy is expensive and many patients cannot tolerate
the serious side effects that may prevent completion of
the treatment course. Although age, sex, host genetics,
body mass index (BMI), HCV genotype, and HCV viral
load are associated with treatment response, finding a
marker that predicts treatment outcome has been diffi-
cult. Therefore it is important to identify the factors that
affect the response to treatment [3].
Several genome-wide association studies have re-
ported that the rs12979860 single nucleotide poly-
morphism (SNP) in intron 1 of interferon l (IFNL)4
gene is strongly associated with sustained virological
response (SVR) [4,5]. Previously, rs12979860 SNP was
recognized as a polymorphism of IL28B gene [5].
IFNl genes located on chromosome 19 belong to the
family of type III interferon. Different IFNl genes are
recognized, including IFNl1 (IL29), IFNl2 (IL28A),
IFNl3 (IL28B), and IFNl4, which have all been shown
to possess antiviral activity in vivo and in vitro [6].
Many studies have demonstrated that the rs12979860 C
allele favors response to antiviral treatment of chronic
HCV infection [7,8].
Several methods, such as direct DNA sequencing,
real-time polymerase chain reaction (PCR), amplifica-
tion refractory mutation system (ARMS)-PCR, PCR-
restriction fragment length polymorphism (RFLP), and
allele-specific PCR can be used for genotyping SNPs,
such as IL28B alleles [9].
This study had two aims: to evaluate the specificity,
sensitivity, cost, and turn-around time of three methods
of gene polymorphism analysis and to study the rela-
tionship between IL28B rs12979860 and SVR rate to
pegIFN-a/RVB therapy among patients with chronic
hepatitis C (CHC).2. Materials and methods
2.1. Patients
The study examined outcomes in 100 patients with
CHC in two provinces of Iran, including Tehran
(Digestive Disease Research Institute) and Kerman
(Virology Laboratory of the Besat Specialist Clinic)criteria included having other hepatitis viruses, using
immunosuppressive drugs (organ transplantation), and
having any diseases that suppress the immune system
(human immunodeficiency virus).
2.2. Treatment of patients
All the patients were treated with 180 mg/wk
PegIFNa-2a and 1,000e1,200 mg/d RBV. The patients
with chronic HCV genotypes 1 and 3 were treated for
48 weeks and 24 weeks, respectively [10]. The viral load
(HCV RNA) in blood was measured at the end of the
treatment and 6 months later. The absence of detectable
HCV RNA in blood for at least 24 weeks after dis-
continuing treatment was defined as an SVR.
2.3. Sample collection
Blood samples (8 mL) from HCV patients were
collected in EDTA tubes. Plasma was separated and
aliquoted. Then, it was stored at 80C until analysis.
Peripheral blood mononuclear cells were isolated using
Ficoll (Ficoll-Paque PLUS; GE Healthcare) and stored
at 20C.
2.4. RNA and DNA extraction
HCV RNA was extracted from 200-mL plasma
samples using a high pure RNA isolation kit (Roche,
Germany). Purified RNA was stored at 80C for later
analysis. IL28B DNA was extracted from 200-mL pe-
ripheral blood mononuclear cell samples using a high
pure PCR template preparation kit (Roche). Purified
DNA was used directly or stored at 2e8C or 15e25C
for later analysis. DNA and RNA concentrations were
detected by calculating the absorbance ratio of optical
density at 260/280 nm using Thermo Scientific
NanoDrop-2000 model (Wilmington, DE, USA).
2.5. Virological testing
HCV genotyping and viral loading from plasma
samples were carried out using the AmpliSens HCV-1/
2/3-FEP PCR kit and AmpliSens HCV-Monitor-FRT
(InterLabService Ltd., Moscow, Russia).
2.6. Laboratory procedures
Liver enzyme function tests were carried out for all
the patients. Alanine aminotransferase (ALT), aspartate
aminotransferase (AST), and alkaline phosphatase
(ALP) were measured on the Selectra E Clinical
Chemistry analyzer (Vital Scientific, The Netherlands).
2.7. PCR-RFLP
The IL28B polymorphism (rs12979860) was detected
following PCR-RFLP amplification using forward
primer: 50-CTCTGCACAGTCTGGGATTCCT-30 and
reverse primer: 50-CTGAGGGACCGCTACG-
TAAGTC-30. The amplification reaction mixture con-
sisted of 50 ng genomic DNA, forward and reverse
Comparison of three methods for the detection of IL28 rs12979860 85primers (0.15mM of each), different deoxynucleotides
(0.2mM of each), Ex Taq DNA Polymerase (1.5 U)
(Takara Korea Biomedical Inc.), and PCR buffer (10)
containing 1.5mM MgCl2. First, PCR was performed by
denaturing the samples (10 minutes at 95C), followed
by 35 cycles including 95C for 45 seconds, 64C for
45 seconds, 72C for 30 seconds, and final extension at
72C for 10 minutes. Electrophoresis of the PCR prod-
ucts was carried out on the agarose gels (2%). For RFLP
analysis, the PCR product (390 bp) of rs12979860 was
digested with 5 U Bsh1236I (BstUI) with Tango buffer
(Fermentas, Vilnius, Lithuania) for 3 hours. The diges-
tion products were visualized on a 3% agarose gel
alongside the GeneRuler Ultra Low Range DNA Ladder
10e300 bp (Fermentas; Figure 1).
2.8. ARMS-PCR
The IL28B polymorphism (rs12979860) was detected
following ARMS-PCR amplification using rs12979860
(T allele) forward primer: 50-GGAGCTCCCC-
GAAGGCGT-30 and reverse primer: 50-
CGAGTGTCTGGGCCGCAG-30 and the rs12979860
(C allele) forward primer: 50-GAGCTCCCC-
GAAGGCGC-30 and reverse primer: 50-
GCTGCCAAGGCGCTGAGG-30. Forward primers
were bound to mutant allele and reverse primers wereFigure 1. IL28B rs12979860 RFLP-PCR genotyping. Lane
L, DNA marker; Lane No. 1 is genotype TT (89 bp, 118 bp,
and 183 bp), Lane No. 2 is genotype CC (25 bp, 89 bp and
183 bp), and Lane No. 3 is genotype CT (25 bp, 89 bp, 118 bp,
and 183 bp).bound to another region; so, different fragment lengths
were obtained. PCR was done in a single tube contain-
ing 25 mL reaction buffer with the following compo-
nents: genomic DNA (50 ng), forward and reverse
primer (0.15mM of 4 primers), different deoxynucleo-
tides (0.2mM of each), Ex Taq DNA Polymerase (1.5 U;
Takara Korea Biomedical Inc.), and PCR buffer (10)
containing 1.5mM MgCl2. Cycling parameters were
initial denaturation at 95C for 10 minutes, followed by
35 cycles including 95C for 45 seconds, 66C for
45 seconds, 72C for 45 seconds, and final extension at
72C for 10 minutes. Electrophoresis of the PCR prod-
ucts was done on 2% agarose gels (Figure 2).
2.9. PCR sequencing
Direct sequencing was performed by the Sanger
method (Source BioScience Launches New Illumina
MiSeq Next Generation DNA Sequencing Service) with
the PCR primers described above. The raw sequencing
data was analyzed using CLC Main Workbench (CLC
Bio, Aarhus, Denmark).
2.10. Ethics statement
The current study was approved by the Ethical
Committee of the School of Public Health, Tehran
University of Medical Sciences, Tehran, Iran. Informed
consent was also obtained directly from each patient.Figure 2. IL28B rs12979860 ARMS-PCR genotyping. Lane
L. DNA marker; Lane No. 1 is genotype CT (326 bp and
443 bp), Lane No 2 is genotype CC (326 bp), and Lane No. 2 is
genotype TT (443 bp).
Table 1. Characterization, clinical, and virological properties of Iranian patients with CHC before anti-viral therapy with
pegylated interferon-a2a/ribavirin.
Variables Patients
HCV genotype 1a 3a Total p
No. (%) 51 (51) 49 (49) 100 (100)
Age (y) 52.8  4.7 51.7  4.6 52.2  4.6 0.259
Laboratory parameters
AST (IU/L) 261.3  203.8 217.3  191.6 239.3  197.7 0.310
ALT (IU/L) 274.0  230.1 227.2  228.3 250.6  229.2 0.269
ALP (IU/L) 692.3  487.7 618.7  397.6 655.5  442.6 0.411
HCV viral load (IU/mL) 4.9  106  2.5  106 3.7  106  2.2  106 4.3  106  2.4  106 0.018
Continuous parameters are presented as mean  standard deviation. ALP Z alkaline phosphatase; ALTZ alanine aminotransferase; ASTZ aspartate
aminotransferase; HCV Z hepatitis C virus.
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3.1. Patient characteristics
One hundred patients (84 male and 16 female) with
chronic HCV infection were followed up in this study.
There were 51 patients with HCV genotype 1a infection
and 49 patients with HCV genotype 3a infection. The
mean age of the patients was 52.2  4.6 years (range,
41e61 years). Pretreatment clinical and virological char-
acterizations includingALT,AST, (ALP),HCVgenotype,
and HCV viral load are shown in Table 1. There were no
significant differences between HCV genotypes and age,
ALT, AST and ALP levels, although there was a signifi-
cant difference from HCV viral load (pZ 0.018).
3.2. Comparison of three different methods for
detection of IL28B rs12979860
A total of 100 samples were analyzed in parallel
using the three methods. The different profiles for IL28B
rs12979860 alleles (CC, CT, and TT) obtained with
PCR-RFLP, ARMS-PCR, and direct sequencing were
consistent among the three methods (Table 2).
3.3. Prevalence of rs12979860 genotype
according to HCV genotypes
In the current study, prevalence of rs12979860 ge-
notypes CC, CT and TT in HCV genotype 1a was 10
(19.6%), 35 (68.6%), and six (11.8%), respectively, and
in HCV genotype 3a, it was 13 (26.5%), 31 (63.3%), and
five (10.2%), respectively (Table 3). No significantTable 2. Analysis of IL28B rs12979860 polymorphisms in 100
using three different methods.
Method
IL28B locus rs12979860
CC (%) TT (%)
PCR-RFLP 23 (23) 11 (11)
ARMS-PCR 23 (23) 11 (11)
Direct sequencing 23 (23) 11 (11)
ARMS Z amplification refractory mutation system; PCR Z polymerase chaidifference was seen between rs12979860 genotype and
HCV genotype (p Z 0.710).
3.4. SVR rates according to rs12979860
genotypes
The SVR rate in patients with HCV genotype 1a and
3a infection was 18 (35.3%) and 38 (77.5%), respec-
tively. SVR rate in patients with HCV genotype 1a
infection was significantly less than in patients with
HCV genotype 3a infection (p < 0.001). Among the
HCV genotype 1a and 3a groups, 33 (64.7%) and 11
(22.45%) patients were non-responders (non-SVR;
Table 4).
Among 18 (35.3%) patients with HCV genotype 1a
infection, frequency of rs12979860 CC, CT, and TT
genotypes in SVR patients was six, 11, and one,
respectively, while in non-SVR patients, the frequency
was four, 24, and five, respectively. CC genotype of
rs12979860 was significantly associated with SVR
compared to non-CC genotype (p Z 0.032; Table 3).
For 38 patients with HCV genotype 3a infection,
frequency of rs12979860 CC, CT, and TT genotypes in
SVR patients was 12, 23, and three, respectively. By
contrast, in non-SVR patients, the frequency was one,
eight, and two, respectively. Two (CC and CT) geno-
types of rs12979860 were significantly associated with
SVR (p Z 0.032; Table 3).
Multiple logistic regression analysis identified two
independent factors that were significantly associated
with SVR: IL-28B genotype (rs 12979860 CC vs. TTpatients with chronic hepatitis C virus genotype 1a and 3a
Cost Turnaround timeCT (%)
66 (66) US$4.70 6 h 45 min
66 (66) US$3.10 2 h 40 min
66 (66) US$16.20 2 d
n reaction; RFLP Z restriction fragment length polymorphism.
Table 3. Relationship between baseline demographic, clinical, virological characteristics and sustained virological responders
with rs12979860 IL28B polymorphisms.
IL28B rs12979860
Variable CC CT TT p
HCV genotype (1a/3a) 10/13 35/31 6/5 0.710
Baseline viral load (IU/mL) 3.3  106  1.7  106 4.6  106  2.5  106 4.5  106  2.4  106 0.127
AST (IU/L) 243.4  240.1 253.0  183.3 239.7  206.9 0.661
ALT (IU/L) 248.8  245.9 262.2  217.3 251.1  213.3 0.689
ALP (IU/L) 586.4  360.7 558.7  481.6 656.3  356.0 0.569
SVR 18 34 4 0.032*
Non-SVR 5 32 7
*Statistically significant. ALP Z alkaline phosphatase; ALT Z alanine aminotransferase; AST Z aspartate aminotransferase; HCV Z hepatitis C virus;
SVR Z sustained virological response.
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HCV genotypes (odds ratio, 7.42; Table 5).Table 5. Results of multivariate regression analyses of
the factors associated with sustained virological4. Discussion
For SNP genotyping, Genome-Wide human SNP
array, Genotyping Bead Chip, and the Invador method
are used in the genome-wide association study stage
[11]. DNA sequencing, TaqMan 50 allelic discrimination
method [12,13], and ARMS-PCR with or without tetra-
primer [14,15] are used in the screening stage.
Several SNP genotyping methods have developed in
recent years and many strong methods are currently
available. The demand for SNP genotyping is great,
however, and no one method is able to meet the needs of
all studies using SNPs. Despite the considerable gains
over the past decade, new methods must be developed to
lower the cost and increase the speed of SNP detection
[16].
In the present study, PCR-RFLP, ARMS-PCR, and
sequencing were effective and specific in determining
the IL28B rs12979860 genotypes. The electrophoresis
pattern of the genotyping samples is shown in Figures 1
and 2. IL28B rs12979860 genotypes were successfully
determined in all patients using the three methods.
Among 100 patients with chronic HCV-1a and 3a
infection, CC, CT, and TT genotypes accounted for 23%
(23/100), 66% (66/100), and 11% (11/100), respectively.
Besides gene sequencing, other methods with high
sensitivity, such as PCR-RFLP, ARMS-PCR SNPTable 4. Relationship between virus genotype and SVR.
Patient features SVR Non-SVR Total p
No. of patients
(%)
56 44 100 d
HCV genotype
1a 18 (35.3) 33 (64.7) 51 (100) < 0.001*
3a 38 (77.5) 11 (22.5) 49 (100)
*Statistically significant. Data are presented as n (%). HCV Z hepatitis
C virus; SVR Z sustained virological response.detection have been utilized for gene mutation detection.
As for costs, excluding sample extraction that is com-
mon in all three methods, a single IL28B polymorphism
determination was estimated to cost US$4.70 when
performed using PCR-RFLP, US$3.10 using ARMS-
PCR, and US$16.20 using sequencing. Turnaround time
was 6 hours 45 minutes when performing PCR-RFLP,
2 hours 40 minutes when performing ARMS-PCR and
2 days for sequencing. Both PCR-RFLP and ARMS-
PCR showed higher sensitivity with respect to direct
sequencing.
Several studies have used PCR-RFLP for deter-
mining rs12979860 polymorphism. Nakamoto et al [17],
Sharafi et al [18], and Irman et al [8] have utilized PCR-
RFLP for detecting rs12979860. They have reported that
this method is valid, fast, simple, and cost-effective for
genotyping common IL28B SNPs and can be readily
adopted by any molecular diagnostic laboratory with
PCR-RFLP capability, and will be clinically beneficial
in predicting treatment response in patients with HCV
genotype 1 infection.
Thus, PCR-RFLP for detecting IL28B rs12979860
genotype appeared to be suitable for epidemiological
investigations; however, two limitations of this tech-
nology might misdiagnose genotypes in the case of
enzyme incomplete digestions of products and it re-
quires a large amount of sample DNA [19].response in patients with HCV infection.
Characteristic p OR 95% CI
HCV genotype <0.001y 7.42 2.605e21.105
Baseline viral load
(IU/mL)
0.327 1.00 1.000e1.000
IL28 (CC)y 0.067 1
IL28(TT) 0.030b 7.86 1.225e50.511
IL28(CT) 0.048b 4.08 1.010e16.524
yStatistically significant. CI Z confidence interval; HCV Z hepatitis C
virus; OR Z odds ratio.
88 A. Fateh, et alIn this study, we developed a reliable, fast, simple,
inexpensive, sensitive, and specific ARMS-PCR method
for genotyping of IL28B rs12979860 SNPs that is more
cost-effective than PCR-RFLP and sequencing.
Galmozzi et al [14] have developed tetra-primer
ARMS-PCR. This method was rapid, fast, inexpensive
and accurate for detection of rs12979860 polymorphism,
without the need for any special equipment, thus
improving the accessibility to SNP genotyping for all
minimally equipped laboratories.
ARMS-PCR is better than PCR-RFLP and
sequencing considered one of the most cost effective,
and easy to use. By contrast, ARMS-PCR SNP detec-
tion, which uses sequence-specific primers and specific
targets, shows high sensitivity, low costs, and reduced
turnaround time and specificity.
In the current study, frequency of rs12979860 geno-
types CC, CT, and TT in HCV genotype 1a was 10
(19.6%), 35 (68.6%), and six (11.8%), respectively, and
in HCV genotype 3a, it was 13 (26.5%), 31 (63.3%), and
five (10.2%), respectively. The results of the present
study indicate that the IL-28B rs12979860 CT genotype
is the commonest genotype in patients with CHC. These
results were consistent [20] and inconsistent [18] with
other studies.
Different distributions of IL28B rs12979860 genotypes
(protective rs12979860 CC genotype) among Caucasians,
Asians, and Africans describe different rates of SVR in
these populations. Previous studies have confirmed that
rs12979860 CC allele has different frequencies in the
worldwide population: CC genotype frequency in African
populations is 23e55%, 52e80% in European pop-
ulations, 75e98% in Southwest Asian populations, and
90e100% in East Asian populations [21].
Alternatively, various SVR rates might be in part
described by distribution of different rs12979860 alleles
in different HCV genotypes. In the current study, a
lower frequency of CC genotype was found in the HCV-
1a group in comparison with the HCV-3a group. In
addition, it was demonstrated that the rs12979860 CC
genotype was associated with SVR in HCV genotypes 1
and 3. The relationship between IL28B rs12979860
genotype and pegIFN-a/RBV treatment has been
described in different studies [5,22,23]. The present
study showed that CC allele in HCV genotype 1a and
CC/CT alleles in HCV genotype 3a had an important
role in infection control, and SVR rate in the CC group
was higher than in the TT group among Iranian patients
with CHC 1/3. Sharafi et al [18] found that CC and CT
alleles in rs12979860 responded to treatment better than
homozygous TT allele. The effect of rs12979860 poly-
morphism on response to pegIFN-a/RBV treatment in
patients infected with HCV-1 has been extensively
studied. Patients that carried the CC allele had SVR
rates > 80%; so, this genotype is considered to be
favorable. By contrast, patients with the TT allele has
SVR rates < 40%; so, it is considered unfavorable. It isclear which genotyping of the rs12979860 poly-
morphism is a strong predictor of the clinical outcome
for HCV-1 patients [8], but also for HCV-3 to a lesser
extent [24,25].
In the current study, SVR rates in patients with CC,
CT, and TT (IL28B rs12979860) were 18, 34, and
four, respectively. An association was found between
SVR rates and IL28B polymorphisms. Understanding
the associations between various IL28B poly-
morphisms and SVR after treatment with pegIFN-a/
RBV is a major topic, because there is a debate over
whether all untreated patients should receive triple
therapy, given the increased costs and possible
adverse effects. In countries such as Iran, the analysis
of strategies based on IL28B rs12979860 and SVR
could be useful in terms of cost-effectiveness. This
analysis could also provide benefits related to adverse
effects, treatment tolerance, and induction of viral
drug resistance [26].
In conclusion, all three methods are suitable for
determination of IL28B rs12979860 but the ARMS
assay described here was rapid, inexpensive, sensitive,
and accurate for detecting rs12979860 alleles in patients
with CHC. Thus, in our opinion, screening by ARMS-
PCR SNP detection represents the most efficient and
reliable method to determine HCV polymorphisms in
routine clinical practice. We also demonstrated that CC
and CT alleles in HCV-3a and CC allele in HCV-1a
were significantly associated with response to pegIFN-
a/RBV treatment. The present results may help identify
patients for whom therapy might be successful.Conflict of interest
The authors declare no conflicts of interest.
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